The Rising Prevalence Of Erectile Dysfunction (ED) To Boost The Human Chorionic Gonadotropin (HCG) Market Growth
Human Chorionic Gonadotropin (HCG) Market |
Human
Chorionic Gonadotropin (HCG) Market is Segmented
by Product (Naturally Extracted and Recombinant), Application (Male Hypogonadism,
Female Infertility Treatment, Oligospermic Treatment, and Other Applications),
By End User (Ambulatory Surgical Centers , Hospitals and Specialty Clinics) -
Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2023– 2030
Global
Human
Chorionic Gonadotropin (HCG) Market is estimated to be valued
at US$ 710.88 Million in 2022 and is expected
to exhibit a CAGR of 6.5% during the forecast
period (2022-2030), as highlighted in a new report published by
Coherent Market Insights.
Market
Overview:
Human
Chorionic Gonadotropin is a hormone generated by a women during
pregnancy. It is produced in placenta. It is often known as the pregnancy
hormone due to its ideal role in assisting a pregnancy. Human chorionic
gonadotrophin is seen in the urine or blood for over 10 to 11 days post
conception. The Human chorionic gonadotrophin levels are high towards the last
of the first trimester, further waning for the rest of the gravidness.
Competitive
Landscape:
Key players
involved in the growth of global Human Chorionic Gonadotropin (HCG) Market are
Merck & Co. Inc., Merck KGaA, Lupin Limited, Sanzyme, and Fresenius SE
& Co. KGaA.
Market
Key Drivers:
The rising
prevalence of erectile dysfunction (ED) is expected to augment the growth of
global Human Chorionic Gonadotropin
(HCG) Market. For instance, as per BMC Endocrine disease in July 2021,
erectile dysfunction (ED) was reported to be high in around 72.2% of people
across the globe.
The rising
prevalence of infertility in women is also projected to propel the growth of
global Human Chorionic Gonadotropin (HCG) Market. For instance, as per CDC,
March 2022, around 22% couples in which the female is aged around 30 to 39
years have difficulty in conceiving their first child.
Covid-19
Impact Analysis:
The Covid-19
outbreak has adversely affected the growth of global Human Chorionic Gonadotropin (HCG) Market due to the surge in
pandemic as there was rising shift of providers in curing the Covid-19
patients. The delay in treatment of the other disorders and rising social
distance policy has impeded the market growth.
Key
Takeaways:
The global Human Chorionic Gonadotropin (HCG) Market is
anticipated to exhibit a CAGR of 7 % during the forecast period owing to the rising
infertility in women. For instance, as per NLM in December 2021, the total
cases of infertility was around 24.58%, with 6.54% of female experiencing first
infertility.
Among
regions, North America, Europe and Asia Pacific are expected to witness robust
growth in global Human Chorionic Gonadotropin (HCG) Market due to increasing cases
of infertility, rising healthcare infrastructure, increasing reimbursement
policies and increasing adoption of ART. For instance, as per CDC, in U.S,
around 11% of female and 9% of male of childbearing age have
infertility problems.
Comments
Post a Comment